Drugs Made In America Acquisition II Quarterly Cash Flow Statement
NASDAQ: DMIIFinanceBlank ChecksUSD
10.190.00 (0.00%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Drugs Made In America Acquisition II free cash flow
In the quarter ended Jun 30, 2026, Drugs Made In America Acquisition II generated -$172,746 of operating cash flow. That left free cash flow of -$172,746.
Summary generated from market data by MetaCap's automated system. Methodology
Drugs Made In America Acquisition II cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | 4.40M | 4.34M | 4.33M | -46.16K | -38.07K | -59.33K |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Change in Working Capital | -21.71K | -22.25K | 177.27K | 2.43K | -9.12K | 11.28K |
| Operating Cash Flow | -172.75K | -102.50K | -314.86K | -690.73K | -2.60K | -10.04K |
| Investing Cash Flow | — | — | 0 | — | — | — |
| Financing Cash Flow | 0 | 450.00K | 0 | — | — | — |
| Net Change in Cash | -172.75K | 347.50K | -314.86K | 310.69K | -2.60K | -10.04K |
| Free Cash Flow | -172.75K | -102.50K | -314.86K | -690.73K | -2.60K | -10.04K |
This table shows 6 quarterly periods of Drugs Made In America Acquisition II's cash flow statement, from Q2 2026 back to Q1 2025, across 7 line items including net income, change in working capital, operating cash flow. Values in USD; B = billions, M = millions. Fiscal periods follow DMII's reporting calendar. What is a cash flow statement?